Well being of Obstetric patients on Minimal Blood transfusions
Go to the WOMB website.
The study started in May 2004 and is at the moment ongoing in 15 hospitals in The Netherlands, which are collaborating in several proposed studies.
Women with PPH or a decrease in Hb, 12 to 24 hours after delivery or caesarean section.
The sample size will be 400 patients: 200 patients after a VD (where 100 patients receive a
• Blood loss during delivery = at least 1000 mL and/or a peripartum decrease in Hb of at least 1.2 mmol/L
• Hb level of 3.0 - 4.9 mmol/L, 12 to 24 hours after a vaginal delivery or caesarean section
• Women older than 18 years of age
• Good working knowledge of the Dutch language
• Severe preeclampsia or HELLP syndrome
• Serious physical complaints (tachycardia of more than 100 bpm, dyspnoea, syncope, heart problems)
• Severe active infectious disease at the time of proposed inclusion
• Compromised immunological status, congenital or acquired by medical treatment or infectious disease (eg. HIV)
• Severe cardiac, pulmonary, neurological, metabolic or psychiatric co-morbidity (ASA II/
• Peripartum death of the newborn, or the newborn being in critical condition on neonatal intensive care
Patients will be randomised for a
Primary outcome in this study is fatigue measured with the
The total follow-up period is 6 weeks. HRQoL will be measured at T=0 (12-24 hours postpartum) 3 days, 1, 3 and 6 weeks postpartum. At T=0 and 6 weeks postpartum Hb value will be measured as well as a screening on irregular antibodies. For the patients who receive a
Landsteiner Foundation for Blood Research
The medical ethical review board of Erasmus MC, University Medical Center Rotterdam, approved this study.